Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Bristol Myers Squibb Co would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments and shield itself from competition posed by Merck & Co’s Keytruda on its for its cancer immunotherapy, Opdivo.
The deal gives Bristol Myers, which acquired pharmaceutical company Celgene last year for $74 billion, access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten.
According to David Nierengarten, a Wedbush analyst, mavacamten is expected to be a “multi-billion dollar asset” as sales estimates for the treatment of obstructive hypertrophic cardiomyopathy (HCM) is expected to reach about $2.5 billion by 2026.
Hypertrophic cardiomyopathy is estimated to affect one in every 500 people globally.
MyoKardia expects to submit a marketing application to the US health regulator for mavacamten as an obstructive HCM treatment in the first quarter of 2021.
Bristol Myers' portfolio of heart drugs includes blood thinner Eliquis, which made up about 21 percent of the company’s total sales in its latest reported quarter.
